Hyperfine (HYPR) Q4 2024 earnings summary

Executive summary

• Achieved $12.9 million in 2024 revenue, up 17% year-over-year, with significant gross margin expansion and reduced cash burn.

• First FDA-cleared, AI-powered portable MR brain imaging system with proprietary technology and broad labeling, addressing unmet global healthcare needs.

• Completed a reorganization to lower operating costs and raised $6 million to extend cash runway to end of 2026.

• Strategic focus on diversification and expansion into office, hospital, and international markets, with new software launches planned for 2025.

• Highly experienced leadership team with a proven track record in medtech and imaging.

Financial highlights

• Q4 2024 revenue was $2.32 million, down from $2.69 million in Q4 2023, due to longer deal cycles and lower ASP from international mix.

• Full-year 2024 revenue reached $12.9 million, a 17% increase over 2023; 48 systems sold vs. 37 in 2023.

• Gross profit for 2024 was $5.89 million, up 24% year-over-year; gross margin expanded to 46%, up from 43% in 2023.

• Net loss for 2024 was $40.72 million ($0.56/share), improved from $44.24 million ($0.62/share) in 2023.

• Cash and equivalents at year-end were $37.64 million; 2024 net cash burn was $38.4 million, down 9% from 2023.

Outlook and guidance

• 2025 revenue expected to grow 20%-30% over 2024, with first-half revenue guidance of $6 million.

• Gross margin guidance for 2025 is 47%-52%, with second half expected to exceed first half.

• 2025 cash burn expected at $25-$27 million, a 32% decline at midpoint; cash runway projected through end of 2026.

• Anticipates business acceleration in second half of 2025, driven by new product launches and expanded market reach.

• Ongoing innovation with next-gen AI-powered software releases planned through 2025.